The US Drug Enforcement Administration (DEA) has finalised Schedule I placement for five “designer benzodiazepines” by adding clonazolam, diclazepam, etizolam, flualprazolam and flubromazolam to Schedule I of the Controlled Substances Act (CSA). The final rule was published on 2 March 2026 and takes effect on 1 April 2026, making permanent the full set of Schedule I controls and sanctions for anyone handling these substances. (Federal Register FR Doc. 2026-04112, 91 FR 9985.)
The rule applies to the named substances and their salts and isomers where applicable. DEA describes them as central nervous system depressants structurally and pharmacologically related to classical benzodiazepines such as alprazolam, with effects including sedation, amnesia and respiratory depression.
For regulated organisations, the practical impact of Schedule I placement is that activities such as manufacture, distribution, reverse distribution, import, export, research, instructional activity, chemical analysis and possession now sit under Schedule I controls on an ongoing basis.
DEA previously issued a temporary Schedule I order on 26 July 2023, later extended until 26 July 2026. The new final rule converts those temporary controls into permanent scheduling following an HHS scientific and medical evaluation (June 2025) and DEA’s eight-factor analysis.
DEA cites three core Schedule I findings: high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. DEA also notes the action supports US obligations under the 1971 UN Convention on Psychotropic Substances, under which these substances were internationally scheduled.
Organisations that may encounter reference standards or research materials should reassess controlled substance governance. DEA highlights requirements spanning registration, security, labelling and packaging, quota (for manufacturers), biennial inventories, records and reporting, and import and export controls.
A practical next step is to map any holdings and workflows involving these substances, confirm registration status where needed, and plan transfers or compliant disposal before the 1 April 2026 effective date.
DEA’s final rule confirms Schedule I placement for clonazolam, diclazepam, etizolam, flualprazolam and flubromazolam from 1 April 2026. The decision locks in strict, long-term US controls for handling and research, and raises the compliance bar for laboratories, suppliers and logistics teams that may store, test, ship or import these substances.
The SUPER BUGS Act 2026 establishes a global framework for pandemic product development, targeting antimicrobial resistance and international collaboration. It introduces regulatory, commercial, and supply chain implications for chemicals and manufacturing stakeholders, reinforcing the need for proactive compliance and strategic positioning.
Engineered biofertilizers offer cost, yield, and environmental benefits but face regulatory ambiguity in the U.S. Clarifying definitions and frameworks will be essential to unlock innovation, ensure compliance, and maintain competitiveness in a growing global market.
Defra’s UK POPs Regulation 2026 consultation proposes adding five substances to the prohibition list, alongside new thresholds and exemptions. With implementation expected by December 2026, businesses must assess supply chain exposure, regulatory divergence and transition requirements.
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
